Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066

International Journal of Oncology
Cong-Cong ChengYi Ding

Abstract

Doxorubicin (Dox) is widely used in the treatment of triple-negative breast cancer cells (TNBCs), however resistance limits its effectiveness. Cancer stem cells (CSCs) are associated with Dox resistance in MCF-7 estrogen receptor positive breast cancer cells. Signal transducer and activator of transcription 3 (Stat3) may functionally shift non-CSCs towards CSCs. However, whether Stat3 drives the formation of CSCs during the development of resistance in TNBC, and whether a Stat3 inhibitor reverses CSC-mediated Dox resistance, remains to be elucidated. In the present study, human MDA-MB-468 and murine 4T1 mammary carcinoma cell lines with the typical characteristics of TNBCs, were compared with estrogen receptor-positive MCF-7 cells as a model system. The MTT assay was used to detect cytotoxicity of Dox. In addition, the expression levels of CSC-specific markers and transcriptional factors were measured by western blotting, immunofluorescence staining and flow cytometry. The mammosphere formation assay was used to detect stem cell activity. Under long-term continuous treatment with Dox at a low concentration, TNBC cultures not only exhibited a drug-resistant phenotype, but also showed CSC properties. These Dox-resistant TNBC cell...Continue Reading

References

Jun 6, 2007·Proceedings of the National Academy of Sciences of the United States of America·Piero DalerbaMichael F Clarke
Oct 4, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jiangbing ZhouYing Zhang
Apr 17, 2008·Cell Cycle·Yuin-Han LohHuck-Hui Ng
May 1, 2008·Journal of the National Cancer Institute·Xiaoxian LiJenny C Chang
Sep 11, 2008·Proceedings of the National Academy of Sciences of the United States of America·Noga Bloushtain-QimronKornelia Polyak
Nov 13, 2008·Cancer Immunology, Immunotherapy : CII·Ling-Yuan KongAmy B Heimberger
Nov 26, 2008·Nature Reviews. Cancer·Natalie Meyer, Linda Z Penn
Dec 17, 2008·PloS One·Benjamin L KidderStephen Palmer
Feb 12, 2009·Cancer Research·Mario-Luca SuvàIvan Stamenkovic
Aug 5, 2010·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Xiao Qi WangSheung Tat Fan
Oct 12, 2010·Journal of the National Cancer Institute·Anna Maria CalcagnoSuresh V Ambudkar
Jan 12, 2011·Proceedings of the National Academy of Sciences of the United States of America·Dimitrios IliopoulosKevin Struhl
Feb 22, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Pål Kristian SelboKristian Berg
Aug 18, 2012·The Journal of Pathology·Philipp Grosse-GehlingLeoni A Kunz-Schughart
Oct 24, 2012·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Sun Jung MyungSu Jong Yu
Dec 25, 2012·Biochemical and Biophysical Research Communications·Yu Kyeong HanChang Geun Lee
Apr 20, 2013·Cancer Cell·Bruno Sainz, Christopher Heeschen
Feb 15, 2014·Annals of the Rheumatic Diseases·Wei GaoUrsula Fearon
Jul 26, 2015·Cancer Letters·Govindasamy-Muralidharan KarthikJohan Hartman
Oct 28, 2015·The American Journal of Chinese Medicine·Ting ZhuGuang-Hui Xiao
Feb 26, 2016·Methods in Molecular Biology·José Rueff, António Sebastião Rodrigues

❮ Previous
Next ❯

Citations

Jul 1, 2020·International Journal of Molecular Sciences·Martina GodelJoanna Kopecka
Apr 29, 2020·International Journal of Molecular Sciences·Yasmin M AttiaGabriel Lopez-Berestein
Sep 27, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ren LiuDong-Sun Lee
Oct 23, 2020·Clocks & Sleep·Fuyuki SatoYasuteru Muragaki
Feb 10, 2021·Clocks & Sleep·Fuyuki SatoYasuteru Muragaki
Feb 23, 2021·Frontiers in Cell and Developmental Biology·Xiaoqing WanYi Ding
Apr 1, 2021·Life Science Alliance·Lohit KheraSima Lev
Apr 10, 2021·Expert Review of Anticancer Therapy·Homa Fatma, Hifzur Rahman Siddique
Oct 16, 2020·Breast Cancer Research and Treatment·Mei ZhouGangadhara R Sareddy
Aug 10, 2021·World Journal of Stem Cells·Nohemí Salinas-JazmínMarco Velasco-Velázquez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.